Stock · COR · Healthcare
United States · Large Cap · listed since 1995 · Revenue 12 mo. $332.8B
Price as of 11/06/2026
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Original text from the data provider
Summary
44.5 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €2.9B (2025), it supports €32B. The remaining €24B of the market value assume it grows 7.9% a year for 10 years and not at all afterwards.
Required FCF growth per year
7.9%
no growth afterwards
Price to operating cash flow 13.4×, within its usual range.
Middle half of 19 quarters: 10.5× to 14.4×, median 11.8×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
5 more unchanged: Revenue, 12 mo., Gross margin, EBIT margin, FCF margin, Shares outstanding
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 103.06% | 11.52% | Rank 100 |
| Return on capital (Greenblatt) | 89.24% | 32.55% | Rank 88 |
| EBIT margin | 1.14% | 18.31% | Rank 7 |
| FCF margin | 1.00% | 14.12% | Rank 7 |
| Gross margin | 3.16% | 60.99% | Rank 0 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 9.31% | 8.04% | Rank 56 |
| Earnings growth, 3 years per year | −0.34% | 5.44% | Rank 34 |
| Earnings growth, 5 years per yeardoes not count towards the rank | – | 7.00% | |
| Sustainable growth (ROE × retained earnings) | 0.21% | 3.66% | Rank 6 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 2.39% | 2.90% | Rank 35 |
| FCF yield | 5.15% | 3.63% | Rank 74 |
| EV/saleslower is better | 0.21 | 4.03 | Rank 97 |
| EV/EBITlower is better | 18.83 | 21.73 | Rank 60 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | −17.01% | 8.66% | Rank 21 |
| Share price, 6 months | 28.25% | 24.27% | Rank 61 |
| Share price, 3 months | 9.22% | 15.42% | Rank 33 |
| Distance from 52-week high | −10.99% | −7.35% | Rank 36 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 3.70% | 0.30% | Rank 23 |
| Change in share countlower is better | −2.53% | 0.00% | Rank 86 |
| Dividend streak in years | 17 | 10 | Rank 79 |
| Price reaction to results, market-adjusted | 3.61% | 0.05% | Rank 77 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 1.97% | 48.40% | Rank 5 |
| Net debt/EBITDAlower is better | 1.70 | 1.11 | Rank 39 |
| Debt to equitylower is better | 7.13 | 0.48 | Rank 0 |
| Volatility, 1 yearlower is better | 31.23% | 31.42% | Rank 52 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $B | Shares | Net debt |
|---|---|---|---|---|---|
| 2016 | 146.8 | 1.2% | 2.7 | 226M | $1.7B |
| 2017 | 153.1 | 1.3% | 1.0 | 222M | $1.4B |
| 2018 | 167.9 | 1.0% | 1.1 | 220M | $2.2B |
| 2019 | 179.6 | 1.0% | 2.0 | 212M | $1.1B |
| 2020 | 189.9 | 1.1% | 1.8 | 205M | $385.4M |
| 2021 | 214.0 | 1.3% | 2.2 | 208M | $6.2B |
| 2022 | 238.6 | 1.2% | 2.2 | 211M | $4.1B |
| 2023 | 262.2 | 0.9% | 3.5 | 205M | $4.1B |
| 2024 | 294.0 | 1.0% | 3.0 | 200M | $3.4B |
| 2025 | 321.3 | 1.1% | 3.2 | 195M | $6.4B |
3 of 7 StockScorer Score rules met · How the score is built
Cencora Inc. mainly meets criteria in the Valuation category. Result from 18 strategies checked.
Cencora Inc. is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
5 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Cencora Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 41.9 | 30.0 |
| P/B ratio | 43.2 | 4.8 |
| Return on equity (ROE) | 103.1% | 11.5% |
| Equity ratio | 2.0% | 48.4% |
| Debt-to-equity (D/E) | 7.13 | 0.48 |
| Dividend yield | 0.7% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| COR | Cencora Inc.this page | |
| CAH | Cardinal Health Inc | Medium5.5 |
| MCK | McKesson Corporation | Low4.5 |
| SIG.AX | Sigma Healthcare Ltd | locked |
| HSIC | Henry Schein Inc | locked |
| M12.DE | M1 Kliniken AG | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.